Scinovex
article Open AccessTop 1% cited

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

BMC Cancer · 2017 · Vol. 17(1) · pp. 332–332
for the ERIVANCE BCC InvestigatorsAleksandar SekulićMichael R. MigdenNicole Basset‐SéguinClaus GarbeAnja GesierichChristopher D. LaoChris MillerLaurent MortierDédée F. MurrellOmid HamidJ. Fernando QuevedoJeannie HouEdward McKennaNatalie DimierSarah WilliamsDirk SchadendorfAxel Hauschild

Abstract

This study was registered prospectively with Clinicaltrials.gov , number NCT00833417 on January 30, 2009.

Hedgehog Signaling Pathway StudiesCancer and Skin LesionsNonmelanoma Skin Cancer StudiesVismodegibMedicineBasal cell carcinomaInternal medicineAdverse effectClinical endpointOncologyCohortSurgeryClinical trial

MeSH terms

AnilidesAntineoplastic AgentsCarcinoma, Basal CellBasal Cell CarcinomaFemaleHumansMaleProspective StudiesPyridinesSkin NeoplasmsSignal TransductionDisease ProgressionATP-Binding Cassette TransportersDisease-Free SurvivalHedgehog Proteins

Funding

  • F. Hoffmann-La Roche
  • Genentech
Citations
407
FWCI
16.79
field-weighted impact
References
25
Percentile
100%
vs. same field & year
Citations per year
References
Metastatic basal cell carcinoma
Journal of the American Academy of Dermatology · 1984 · 539 citations
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
JNCI Journal of the National Cancer Institute · 2000 · 15,689 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.